NOT_YET_RECRUITING
MAAT For Young Adult Cancer Survivors
The goal of this clinical trial is to pilot-test a modified version of telehealth-delivered Memory and Attention Adaption Training (MAAT) that is tailored to young adult childhood cancer survivors (ages 18-39; MAAT-YS) with cancer-related cognitive impairment (CRCI). MAAT-YS consists of 8 weekly visits (45-minutes in duration) and participants use a survivor workbook and complete homework between visits. Participants in this single-group pilot trial (N=9) will complete online self-report measures of cognitive symptoms, quality of life, treatment satisfaction and a brief online neuropsychological test battery at baseline and post-MAAT-YS timepoints.
Conditions:
🦠 Cancer
🗓️ Study Start (Actual) 30 September 2024
🗓️ Primary Completion (Estimated) 30 November 2024
✅ Study Completion (Estimated) 30 November 2024
👥 Enrollment (Estimated) 9
🔬 Study Type INTERVENTIONAL
📊 Phase NA
Locations:
📍 Indianapolis, Indiana, United States
📍 Pittsburgh, Pennsylvania, United States
📍 Memphis, Tennessee, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • 1. Adults aged 18-39
    • 2. Diagnosed prior to 18 years of age with non-CNS solid tumor or leukemia/lymphoma without known CNS involvement
    • 3. At least 1 year after completion of treatment including chemotherapy, cancer-free
    • 4. English fluent
    • 5. Memory or other cognitive problems attributed to cancer and/or cancer treatment
    • 6. Score of \<10 on the FACT-Cog Impact on Quality of Life Scale
    • 7. Willing to use telehealth with internet access
    • 8. Willing to provide informed consent to participation

    Exclusion Criteria:

    • 1. Severe non-cancer brain injury such as severe traumatic brain injury, stroke or toxic injury causing memory impairments;
    • 2. Currently meeting Diagnostic and Statistical Manual-5 (DSM-5) criteria for a severe psychiatric disorder, including substance abuse, mood, anxiety, or psychotic disorders, as assessed by the PRIME-MD;
    • 3. Scoring 3 or below on the 6-item cognitive screen designed to detect severe memory disorders;59
    • 4. Severe uncorrected sensory impairment (severe hearing or visual impairment).
Ages Eligible for Study: 18 Years to 39 Years (ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 10 November 2023
  • First Submitted that Met QC Criteria 27 November 2023
  • First Posted 30 November 2023

Study Record Updates

  • Last Update Submitted that Met QC Criteria 26 July 2024
  • Last Update Posted 30 July 2024
  • Last Verified July 2024